IMRT/VMAT时代头颈肿瘤患者颌骨放射性骨坏死发生率及部位特异性危险因素:大型医院队列研究
该研究回顾性分析6199例2006-2020年间接受根治性放疗的头颈肿瘤患者,评估颌骨放射性骨坏死(ORN)的发生率、潜伏期及危险因素。总体ORN发生率为4.5%,IMRT/VMAT较2D/3D放疗未显著降低总体风险,但显著降低鼻咽癌亚组风险并延迟发病。非鼻咽癌诊断、晚期临床分期、拔牙、不良口腔习惯及异常体重指数为独立预测因素。
要点
- 总体ORN发生率4.5%,口腔癌最高(7.9%),尤其牙龈和口底亚部位。
- IMRT/VMAT显著降低鼻咽癌ORN风险(1.6% vs 5.4%,p=0.006)并延迟发病(26 vs 18个月,p=0.021)。
- 拔牙(aHR 3.21)、非鼻咽癌诊断(aHR 2.71)、晚期分期(aHR 1.66)、不良口腔习惯(aHR 1.45)及异常BMI(aHR 1.45)为独立预测因素。
核心结论
- IMRT/VMAT时代头颈肿瘤放疗后ORN总体发生率为4.5%,IMRT/VMAT可降低鼻咽癌ORN风险并延迟发病,但总体风险未显著降低。
研究设计与样本
- 回顾性分析6199例2006-2020年间接受根治性放疗的头颈肿瘤患者,ORN定义为暴露坏死颌骨持续超过3个月且无肿瘤复发。
主要发现
- 278例(4.5%)发生ORN,2D/3D放疗后发生率为5.5%,IMRT/VMAT后为4.4%,总体无显著差异。
- 鼻咽癌患者中IMRT/VMAT显著降低ORN风险(1.6% vs 5.4%,p=0.006)。
- 口腔癌ORN发生率最高(7.9%),尤其牙龈和口底亚部位。
- ORN中位潜伏期为24个月(四分位距12-44),IMRT/VMAT后较2D/3D放疗更长(26 vs 18个月,p=0.021)。
- 多因素分析显示非鼻咽癌诊断(aHR 2.71)、晚期临床分期(aHR 1.66)、拔牙(aHR 3.21)、不良口腔习惯(aHR 1.45)及异常体重指数(aHR 1.45)为独立预测因素(均p<0.05)。
临床怎么用
- 对头颈肿瘤放疗患者应进行个体化风险分层,尤其关注口腔癌、非鼻咽癌、晚期分期、有拔牙史、不良口腔习惯及异常BMI者。
- IMRT/VMAT时代仍需重视预防性口腔护理,拔牙是ORN的强预测因素,放疗前后应加强口腔管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Osteoradionecrosis (ORN) of the jaw remains a serious late complication of head and neck cancer (HNC) radiotherapy. Although intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc radiotherapy (VMAT) are expected to reduce ORN risk, large real-world data in the modern era are limited. This study evaluated the incidence, latency, and risk factors of ORN across radiotherapy modalities in a large hospital-based cohort. MATERIALS AND METHODS: We retrospectively analyzed 6199 patients with HNC treated with curative radiotherapy between 2006 and 2020. ORN was defined as exposed necrotic jaw bone persisting for > 3 months without tumor recurrence. ORN incidence was compared between conventional 2D/3D radiotherapy and IMRT/VMAT. Latency to ORN onset was assessed using Kaplan-Meier analysis, and independent predictors were identified using multivariate Cox regression for demographic, tumor-related, treatment-related, and patient-related variables. RESULTS: Overall, 278 patients (4.5%) developed ORN. The incidence was 5.5% after 2D/3D radiotherapy and 4.4% after IMRT/VMAT, without a significant overall difference. However, IMRT/VMAT significantly reduced ORN risk in nasopharyngeal carcinoma (NPC) (1.6% vs. 5.4%, p = 0.006). ORN incidence was highest in oral cavity cancers (7.9%), particularly gingival and floor-of-mouth subsites. Median latency to ORN onset was 24 months (interquartile range 12-44) and was longer after IMRT/VMAT than after 2D/3D radiotherapy (26 vs. 18 months, p = 0.021). Multivariate analysis identified non-NPC diagnosis (adjusted hazard ratio [aHR] 2.71), advanced clinical stage (aHR 1.66), dental extraction (aHR 3.21), adverse oral habits (aHR 1.45), and abnormal body mass index (aHR 1.45) as independent predictors of ORN (all p < 0.05). CONCLUSION: In this large contemporary cohort, ORN occurred in 4.5% of HNC patients after radiotherapy. IMRT/VMAT reduced ORN risk and delayed onset, particularly in NPC. Tumor site, disease stage, dental extraction, oral habits, and nutritional status remain key determinants, underscoring the importance of individualized risk stratification and preventive dental care in the IMRT/VMAT era.
引用
- Wu FY, Ko HH, Kao HF, et al. Incidence and Site-Specific Risk Factors of Jaw Osteoradionecrosis for Head and Neck Patients in the IMRT/VMAT Era: Evidence From a Large, Hospital-Based Cohort. Head Neck. 2026. PMID: 42108397. doi:10.1002/hed.70314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。